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ABSTRACT 
UDP-N-acetyl-D-galactosamine: polypeptide N-acetylgalactosaminyl transferase-6 
(pp-GalNAc-T6) is a member of the N-acetyl-D-galactosamine transferase family. It 
catalyzes the addition of N-acetyl-D-galactosamine to proteins, often the first step in O- 
glycosylation of proteins. Glycosylated proteins play important roles in vivo in the cell 
membrane. These are often involved in cell-cell adhesion, cytoskeleton regulation and 
immune recognition. pp-GalNAc-T6 has been shown to be upregulated in a number of 
types of cancer. Abnormally glycosylated forms of mucin 1 (substrate of the enzyme), 
are used clinically as a biomarker for breast cancer. There is potential for other products 
of the pp-GalNAc-T6 catalyzed reaction to be used. It is also possible that pp-GalNAc- 
T6 itself could be used as a biomarker, since levels of this protein tend to be low in non- 
malignant tissues. pp-GalNAc-T6 has been implicated in malignant transformation and 
metastasis of cancer cells. As such, it has considerable potential as a target for 
chemotherapy. To date, no selective inhibitors of the enzyme have been identified. 
However, general inhibitors of the enzyme family result in reduced cell surface O- 
linked glycosylation and induce apoptosis in cultured cells. Thus, a selective inhibitor 
of pp-GalNAc-T6 is likely to target cancer cells and could be developed into a novel 
anticancer therapy. 
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INTRODUCTION 
UDP-N-acetyl-D-galactosamine: polypeptide N-acetylgalactosaminyl transferase-6 
(pp-GalNAc-T6; EC 2.4.1.41; UniProt: Q8NCL4) is an enzyme first identified in 1999 
[1, 2]. Polypeptide N-acetylgalactosaminyl transferases are classified in the GT27 
family, by the CAZy glycosyltransferase classification [3]. This group of enzymes 
catalyses the addition of N-acetyl-D-galactosamine (GalNAc) to threonine or serine 
residues in proteins using UDP-N-acetyl-D-galactosamine (UDP-GalNAc) as the 
donor, generating an oxygen-linked GalNAc (O-GalNAc) with the release of UDP [4, 
5]. The addition of GalNAc to a peptide is often the first step in the process of 
glycosylation [6]. The second step involves GalNAc: glycosyltransferases adding 
further monosaccharides to the O-GalNAc, in a step-wise process, creating an O-glycan 
chain [7]. O-glycans play important roles in the structure and function of membrane 
proteins, and changes in these proteins are thought to lead to malignant transformation 
of tissues [8]. 
 
Post-translational modification of proteins by glycosylation occurs in the Golgi 
apparatus and endoplasmic reticulum of cells. Like other family members, pp-GalNAc- 
T6 resides on the lumen side of the membrane of the Golgi apparatus [1, 9-11]. It is a 
type II membrane protein, in which its N-terminal tail spans the Golgi membrane [12]. 
When Src is activated, pp-GalNAc-T family members move into the endoplasmic 
reticulum [12]. 
 
pp-GalNAc-T6 is a protein in a family of 20 GalNAc transferases [13]. The family 
members differ in their specificity towards target proteins, although some overlap 
exists. They also differ in the cells in which they are expressed although, again, there 
is overlap [14]. The proteins recognise the serine or threonine glycosylation site on the 
target protein as well as the nearby amino acid residues and secondary structure [15]. 
pp-GalNAc-T1 and pp-GalNAc-T2 have a preference for proteins that have yet to be 
glycosylated and are inhibited by neighbouring glycosylations [16]. However, pp- 
GalNAc-T4 and pp-GalNAc-T10 prefer previously glycosylated proteins [17-19]. pp- 
GalNAc-T6 also appears to be in this latter category [2]. 
 
MOLECULAR GENETICS 
The human GALNT6 gene, encodes pp-GalNAc-T6 and is located on chromosome 12 
at locus 12q13.13. The open reading frame is 1869 base pairs long. The gene has 12 
exons arranged in a pattern very similar to that of GALNT3 [1]. The similarity in 
sequence and the layout of the two genes suggest that it may be a product of a late gene 
duplication event [1, 20]. Phylogenic analysis of the protein sequences show that pp- 
GalNAc-T3 is the most closely related member of the GalNAc family to pp-GalNAc- 
T6, with isoforms pp-GalNAc-T8, 9 and 18 being the most distant (Figure 1). 
 
GALNT6 expression is tissue and developmental stage dependent. It has been shown to 
be upregulated when cells are differentiating, and in malignancy [21-24]. Expression is 
minimal in normal tissues [21]. Northern blot analysis on 26 organ samples was used 
to determine the tissue expression pattern and showed that the presence of the GALNT6 
transcript in tissues from fibroblasts, brain, trachea, pancreas and placenta [1]. 
However, Western blot analyses showed that the pp-GalNAc-T6 protein is barely 
detectable in normal human tissues [21]. 
 
STRUCTURE 
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pp-GalNAc-T6 has a predicted, native molecular mass of 71159 Da and is 622 amino 
acids in length. It was demonstrated that it is 64% similar to its family member pp- 
GalNAc-T3 at the protein level. It differs largely in the first ~140 residues of the N- 
terminal domain, and is largely conserved in the active site and a manganese ion 
binding site. Since no structural data is available on this isoform, a homology model 
was constructed (Figure 2; for details of how the model was constructed see figure 
legend). Key functional regions that have been shown to be important in pp-GalNAc- 
T10 (the only family member for which a high resolution structure has been published, 
PDB: 2D7R; [19]) were used to identify the corresponding parts of pp-GalNAc-T6. 
These analyses predicted that the protein is composed of multiple domains (Figure 2). 
The protein is composed of a hydrophobic membrane spanning signal sequence 
(residues 9-28), an N-terminal, largely random coil cytoplasmic tail, a GT1-type type 
catalytic subdomain A (residues 176-285), and a catalytic subdomain B (residues 348- 
410) joined to an R-type lectin domain (residues 496-622) by a flexible unstructured 
linker. The lectin domain has a typical β-trefoil fold. The cytoplasmic tail has been 
proposed to be involved with peripheral Golgi membrane protein tethering complexes 
[25]. 
 
The length of the linker differs between family members and has been shown to affect 
the specificity of the enzyme. pp-GalNAc-T1 and 2 have longer linkers in comparison 
to the shorter linkers seen in pp-GalNAc-T10 These longer linkers are seen in the 
isoforms that require a substrate that has been already glycosylated. A smaller distance 
between the catalytic and lectin domain and a narrower cleft between them increases 
the effective concentration of the protein substrate aiding the rate of reaction [19]. 
From the model it must be noted that this isoform of the protein has an extended N- 
terminal domain that differs from the other isoforms (Figure 2). It appears in the model 
to be mostly unstructured. This is unlikely to be the case, and it is probably a 
transmembrane region (such regions are typically modelled less well by homology 
modelling software). In the crystal structure of pp-GalNAc-T10 this region was not 
present as membrane spanning regions are often difficult to crystallise [19]. The 
manganese ion binding site is conserved in all pp-GalNAc-T family members. The ion 
binding site has six ligands: two histidine residues (predicted to be residues His271 
and His407 in pp-GalNAc-T6), one asparate (Asp269), two oxygens from the UDP-N- 
acetylgalactosamine substrate and a water molecule [19]. 
 
FUNCTION 
The lectin domain recognises glycosylated polypeptide substrates [26]. The domain 
contains the three repeats of a CCQxW motif, in subdomains α, β and γ. In pp-GalNAc- 
T10 the β subdomain interacts with the GalNAc and it seems likely that the same is true 
in pp-GalNAc-T6 [19]. Threonine residues in the acceptor protein are generally more 
effective galactose acceptors than serines [27]. However, the residues neighboring the 
serine/threonine are also important in determining whether the protein will be a 
substrate or not, particularly in positions -3 and +3 of the acceptor residue. Proline 
residues in positions +1 and +3 also help drive substrate preference, and charged 
residues close by have a negative effect [28, 29]. 
 
MECHANISM 
There has been considerable discussion in the literature about the mechanism of action 
of this family of proteins. Understanding their mechanism would be an important initial 
step for assessing if pp-GalNAc-T6 is a viable drug target. The conservation of the 
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catalytic domain makes it likely that the catalytic mechanism is also well-conserved 
throughout the family. Therefore, studies on other family members are likely to apply 
to pp-GalNAc-T6. 
 
There has been two mechanisms proposed [19, 30]. The first is a double replacement 
mechanism, in which the side chain amide NH2 from Asn-383 (Gln-346 in pp-GalNAc- 
T10) acts as a nucleophile and attacks the anomeric carbon of the GalNAc ring, and 
this leads to the formation of an enzyme-glycosyl intermediate [19]. Asparagine does 
not normally act as a nucleophile; however it has been proposed that the glycosidic 
bond in UDP-GalNAc is strained and is elongated making it very susceptible to 
nucleophilic attack when found in the enzyme binding pocket [19]. The intermediate 
state is proposed to be stabilised by eight hydrogen bonds [19]. The reaction ends when 
the β-phosphate oxygen from the UDP donates electrons to the hydrogen from the 
hydroxyl group of the serine residue of the protein substrate. The Mn2+ interacts with 
the diphosphate and stabilises it [31]. The hydroxyl group then nucleophilically attacks 
the anomeric carbon joining the protein substrate and the GalNAc [19]. Electrons from 
the Asn-GalNAc bond return to the amide of the asparagine. This returns the enzyme 
to its initial state and thus makes it ready of the next UDP-GalNAc substrate [19]. 
 
The other proposed mechanism is a front-side attack mechanism [30]. This was 
postulated as an alternative mechanism because of doubt about the ability of asparagine 
and glutamine to act as nucleophiles as well as the potential nucleophile’s distance from 
the β-phosphate oxygen (approximately 7 Å In pp-GalNAc-T2) [30]. In the front side 
attack mechanism the hydroxyl group of the protein substrate acts as the nucleophile 
attacking the anomeric carbon. This creates an oxocarbenium ion-like transition state 
whereby both the oxygen from the serine residue and the β-phosphate oxygen are 
trivalent. The β-phosphate oxygen then donates electrons to the serine hydroxyl group 
which nucleophilically attacks the anomeric carbon as in the double replacement 
mechanism [32]. 
 
The reaction is believed to be made possible because of the conformational stress that 
causes the anomeric carbon of UDP-GalNAc to be elongated and thus susceptible to 
attack. The intermediate state is stabilised by eight hydrogen bonds with the protein. In 
pp-GalNAc-T10 this is mediated by Gln346 [19]. In the homology model of pp- 
GalNAc-T6 (Figure 2) this corresponds to Asn383. A second nucleophilic attack forms 
a glycosidic bond between the enzyme, UDP-GalNAc and the substrate protein forming 
an intermediate. 
 
The isoforms differ in their kinetic parameters depending on the substrate. Of the 
substrates studied with pp-GalNAc-T6 to date, the highest Vmax has been measured 
with fibronectin (2.37 nmol/min/μg) with a corresponding Km of 3.23 mM. Its Vmax and 
Km are reduced to 1.43 nmol/min/μg and 0.61mM respectively when the substrate is 
HIVHIBgp120 [1]. 
 
 
ROLE IN CANCER 
Expression of pp-GalNAc-T6 is often upregulated in malignant tissue. Dysregulation 
of the gene coding for pp-GalNAc-T6 has been suggested to be an early event in 
tumorgenisis [33]. This can result in increased glycosylation of proteins in sites that 
would normally be unoccupied. This can change the structure and function of these 
5  
proteins making them oncogenic [33]. In malignant tissue glycoproteins such as mucin 
are often truncated, and the O-GalNAc is not extended as expected in non-malignant 
tissue. In adenocarcinomas these are often seen as core antigen carbohydrates (e.g. TF 
and Tn antigens) [34]. Altered tumour-associated core antigens are seen more in 
malignancy than oncogenes. They are also are more strongly associated with cancer 
progression [8]. Correct glycosylation is important in controlling cell-cell interactions, 
a key part in invasion and metastasis. 
 
Mucins are large glycoproteins that have many O-oligosaccharides attached to the 
protein structure. The saccharide units can comprise more than 50% of the mass of the 
mucin [35, 36]. MUC1 is a transmembrane mucin that interacts with EGFRs, ERα, and 
β-catenin [37]. Mucins sterically hinder adhesion molecules enabling the malignant cell 
to more easily become detached and metastasise [38]. Mucins also aid the tumour in 
evading the immune system by preventing immune cells from binding as well as 
stopping antigen presentation [39]. MUC1 has been implicated in mammary cancer 
[21]. Antigens derived from this protein, CA 27.29 and CA 15-3, are biomarkers used 
to predict breast cancer recurrence [40, 41]. The O-oligosaccharides are added to the 
protein by pp-GalNAc-T6 [21]. These glycosylations add stability to the protein and 
play a role in the regulation of the cytoskeleton and proliferation of malignant cells in 
breast cancer [42]. These truncated glycans play a role in altered cell-cell adhesion, 
malignant transformation and cancer metastasis. These breast cancer cells are able to 
evade the immune system due to their different antigenic appearance and the 
breakdown of cell–cell and cell–matrix contacts allows the malignant cells to migrate 
and metastasise [37]. These altered glycosylation patterns can be used as a marker in 
premalignant and malignant cancer [43]. 
 
GalNAc-T6 is expressed in 81% of breast carcinomas [34]. A statistically significant 
correlation was observed between pp-GalNAc-T6 expression and tumour stage in 
breast cancers. pp-GalNAc-T6 is strongly expressed in myoepithelial cells of the breast 
[34]. Myoepithelial cells are seen as ‘natural tumour suppressors’ because they have 
been implicated in angiogenesis, polarity and growth of cancer cells [34]. Knockdown 
of GALNT6 by miRNA in breast cancer cells enhanced cell-cell adhesion and cell 
growth. These cells showed to have increased β-catenin and E-cadherin molecule 
expression than the control cells [21]. pp-GalNAc-T6 has been found to be over 
expressed in the bone marrow of patients with breast cancer, and has been associated 
with cancer recurrence [44]. A statistically significant higher risk of recurrence was 
found in people without lymph node involvement, in comparison to pp-GalNAc-T6 
negative patients. RT-PCR analysis on these cells has been suggested as a way to 
monitor risk of metastasis and response to treatment [44]. 
 
pp-GalNAc-T1, T2, T3 and T6 are expressed in oral cell carcinoma [45-48]. They O- 
glycosylate fibronectin forming glycosylated onco-foetal fibronectin (GOF) in the 
stroma of malignant cells [49]. An O-glycan is added to a threonine in the IIICS domain 
of the fibronectin. GOF has an altered spiral shape, and it is only present in tissues with 
pathology such as in oral carcinoma, breast carcinoma and rheumatoid arthritis [50]. 
The presence of GOF is correlated with survival rates of patients with oral cell 
carcinoma, and either pp-GalNAc-T3 or T6 must be present to allow GOF to form. 
Neither isoform could be detected in stromal fibroblasts but are present in malignant 
cells [49]. In malignant cells, the pp-GalNAc-T6 mediated glycosylation of fibronectin 
tends to result in a large number of short oligosaccharide chains being added to the 
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surface of the protein [21, 51-53]. This stabilizes the fibronectin molecule promoting 
an invasive, cancerous phenotype in the cells [54]. 
 
pp-GalNAc-T6 has been associated with venous invasion in gastric carcinomas, in the 
body of the stomach [9]. It is expressed in 79% of gastric carcinomas tested in 
comparison to 69% in normal gastric mucosa. The percentage was higher in intestinal 
and diffuse type carcinomas (81% and 86%). In the precancerous state of intestinal 
metaplasia the percentage presence dropped to 52% [9]. This may reflect the 
differentiation traits of the tissue. pp-GalNAc-T6 has been suggested as a marker to 
predict venous invasion in gastric carcinoma [9]. 
 
pp-GalNAc-T6 has also been studied once in pancreatic cancer [23, 55]. pp-GalNAc- 
T6 expression is rare in normal ductal epithelium of the pancreas. However it is 
expressed in 51% of patients with pancreatic adenocarcinoma. The expression of pp- 
GalNAc-T6 was mainly seen in early American Joint Committee on Cancer stage, well 
to moderately differentiated, small tumours [55]. In contrast to other cancer types 
studied, pp-GalNAc-T6 positive patients had a longer overall survival time than those 
without the protein. It has been suggested as a prognostic indicator, as in its absence it 
may recommend the use of more aggressive treatment. However, one disadvantage is 
that it is not expressed in undifferentiated cancer [55]. Further study will be required to 
confirm these results as the sample size was limited in this study. In contrast with breast 
and oral cancers it appears that the inhibition of pp-GalNAc-T6 would have a negative 
impact on patients’ survival as it may enhance cancer progression, although the 
mechanism of this is not yet known. 
 
The abnormal glycosylation patterns on malignant cells can be used as biomarkers to 
identify cancer [56]. As many pp-GalNAC-T6 products are associated with the cell 
membrane it makes them more accessible to antibodies. Thus, it is realistic to propose 
that they could be used as therapeutic markers. Some of these highly expressed in 
cancers include Tn, T and STn antigens. Each of these antigens has varying degrees of 
O-glycan chain length and composition [57, 58]. 
 
Bloodstream MUC1 (CA15-3) is currently used as a biomarker of prognosis and 
response to therapy in people with breast cancer. Elevated levels indicate a poor 
prognosis or treatment failure. CA15-3 cannot be used for screening purposes as it is 
not only expressed in breast cancer but also in other cancers, as well as some 
inflammatory conditions such as ovarian hyperstimulation syndrome [59]. pp-GalNAc- 
T6 itself has potential as a biomarker since it is up-regulated in many types of cancer. 
One issue would be the development of antibodies (or other reagents) which could 
reliably recognize this isoform over the other family members. 
 
POTENTIAL AS A DRUG TARGET 
Since pp-GalNAc-T6 is not present in non-cancerous tissues, it is a promising a drug 
target candidate. Inhibition of it would have limited consequences on normal healthy 
tissue, helping to reduce the side effects encountered with many current treatments. It 
has also been suggested that altered O-glycans in tumours could be targeted by vaccines 
[60-62]. However, there are some drawbacks to targeting pp-GalNAc-T6. The 
sequence, structural and mechanistic similarity to pp-GalNAc-T3 may make it 
challenging to find a compound that inhibits only pp-GalNAc-T6. However, given that 
there is some functional redundancy between pp-GalNAc-T3 and pp-GalNAc-T6, there 
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may also be benefits in inhibiting both isoforms in circumstances where both have been 
clearly linked to pathology. pp-GalNAc-T family enzymes are generally assayed by 
the detection of glycosylated peptide products using MALDI-TOF mass spectrometry 
and radioactive substrates [63-65]. These methods would be difficult to carry out with 
a large number of compounds (typically >500,000 in a high throughput screen) [1]. An 
enzyme-linked lectin assay (ELLA) has been developed in which glycosylation of an 
immobilised peptide substrate is detected with a lectin linked to horse radish peroxidase 
[66]. This has some potential for development into a highly parallel, high throughput 
assay format. It has also been difficult to identify efficient GalNAcylation targets and 
sites. However, “SimpleCell" lines have enabled the creation of cell lines that are 
deficient in genes involved in glycosylation [67]. This may improve our understanding 
of members of the GalNAc-T family roles in cells. 
 
To date, only a limited range of inhibitors of pp-GalNAc-T family members have been 
reported. The majority of these are natural metabolites (or close analogues thereof) and 
are, therefore, unlikely to have much potential as drugs. For example, a range of 
nucleotide triphosphates (including ATP, ADP, AMP, CTP, GTP and UTP) inhibit pp- 
GalNAc-T activity purified from the mammary gland of cows [68]. It is not clear what 
isoform(s) were being inhibited in this study (which was performed before the diversity 
of  the  pp-GalNAc-T  family  was  known).  UDP  and  UTP  have  been  shown  to 
competitively inhibit rat and bovine pp-GalNAc-T family members with respect to 
UDP-N-acetylgalactosamine strongly suggesting that these compounds interact at the 
active  site  [69,  70]. N-acetylgalactosamine  and  a  range  of   related  compounds 
(including benzyl, phenyl, p-nitrophenyl and o-nitrophenyl derivatives) have been 
shown to antagonise the interaction between the substrate and the lectin domain [71]. 
UMP-hexadecanesulfonic-anhydride (hexadecane-1-sulfonic (((2R,3S,4R,5R)-5-(2,4- 
dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl 
phosphoric) anhydride; CAS: 134282-88-5;  Scheme  1)  competitively inhibits pp- 
GalNAc-T [72].  The IC50 value was 160 µM, which suggests too low an affinity to be 
a viable drug-like molecule. Furthermore, it seems likely that this compound will be a 
generic inhibitor of the pp-GalNAc-T family and may also affect other enzymes which 
have  UDP  or  UDP-sugars  as  substrates. However,  it  is  possible  that,  through 
modification of this compound, it may be possible to obtain selective inhibitors of 
human pp-GalNAc-T6. It may also be possible to study other substrate analogues, 
including compounds which combine some similarity to both the UDP-N- 
acetylgalactosamine and the polypeptide substrates. 
 
In an alternative approach, a number of UDP-sugar analogues have been synthesised in 
which the carbon-oxygen bond between the sugar and the diphosphate moiety is 
replaced with a carbon-carbon-oxygen bond system [73]. It was hypothesised that these 
would act as competitive inhibitors of enzymes which have UDP-sugar substrates, 
especially those where cleavage of the sugar from UDP is required as part of the 
mechanism [73]. However, these compounds have not been tested for their inhibitory 
potential. Again, it seems likely that they would act relatively non-specifically and that 
considerable medicinal chemistry optimisation would be required before they could be 
considered viable drug leads. 
 
Screening of a library of over 1300 uridine derivatives using an enzyme-linked lectin 
assay (ELLA) identified two compounds which inhibit pp-GalNAc-T1 [66]. Both 
compounds incorporate a trihydroxylated benzene group (Scheme 2).  The IC50 values 
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for inhibition of pp-GalNAc-T1 were in the 20-25 µM range for both compounds [66]. 
They also inhibit other members of the family (with IC50 values in the range 5-40 µM); 
however, pp-GalNAc-T6 was not tested. No inhibition of other sugar transferases was 
detected [66]. These data suggest that these inhibitors are specific to the pp-GalNAc- 
T family, but do not differentiate between family members. One of these compounds 
(1-68A; (E)-2,3,4-trihydroxybenzaldehyde O-(((2R,3S,4R,5R)-5-(2,4-dioxo-3,4- 
dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl) oxime) 
reduced cell surface glycosylation and induced apoptosis [74]. Since this compound 
inhibits several members of the pp-GalNAc-T family with roughly equivalent potency, 
it is not possible to say which family member(s) were the most important in this 
outcome. Nevertheless, these data demonstrate that pp-GalNAc-T family members 
play key roles in cells, with inhibition resulting in apoptosis. Given that pp-GalNAc- 
T6 is up-regulated in a range of different types of cancer and that this may result in 
promotion of the cancerous phenotype (see above), targeting pp-GalNAc-T6 may result 
in the selective induction of apoptosis in cancer cells – a highly desirable outcome in 
cancer chemotherapy. Although the pp-GalNAc family members are likely to be 
similar in structure and catalytic mechanism, there are examples of drugs which 
differentiate between highly similar enzymes. For example, sildenafil (Viagra) 
selectively inhibits one human phosphodiesterase isoform and Clorsulon inhibits highly 
conserved glycolytic enzymes yet selects for helminth parasite enzymes over the 
mammalian host enzymes [75, 76]. 
 
CONCLUSION 
Thus far relatively little structural and biochemical information is available for pp- 
GalNAc-T6. Much of this has been predicted from the properties of other members of 
the pp-GalNAc-T family, and in particular pp-GalNAc-T3 due to its high sequence 
similarity. However from the clinical and tissue based studies that have been carried 
out it seems to have significant potential. It is up regulated in cancer, with little 
expression in other cells. Therefore, it has a variety of possible uses in therapy; it may 
be used as a biomarker itself, as a drug target or a product of its reaction could be used 
as a biomarker. Given that it is particularly involved in metastasis it has the potential to 
be targeted in instances where all other treatment options fail. This protein warrants 
future study. Furthermore, the study of glycosylation events and patterns, and how these 
change in the cancerous state, presents an important frontier in molecular oncology. 
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FIGURE AND SCHEME LEGENDS 
Figure 1: An UPGMA tree with bootstrap analysis (2000 replicates) of the protein 
sequences of the human pp-GalNAc-T family [77, 78]. The distances were computed 
using the Poisson correction method and are in the units of the number of amino acid 
substitutions per site [79]. The analysis involved 19 amino acid sequences. All positions 
containing gaps and missing data were eliminated. There were a total of 448 positions 
in the final dataset. Sequences were aligned using ClustalW [80] and the tree generated 
using MEGA 7 [81-83]. The alignment includes all currently known pp-GalNAc-T 
isoforms and also proteins classified as “UDP-N-acetyl-D-galactosamine:polypeptide 
N-acetylgalactosaminyltransferase like” (pp-GalNAc-TL). pp-GalNAc-T15 is also 
known as pp-GalNAc-T2L, pp-GalNAc-T16 as pp-GalNAc-T1L, pp-GalNAc-T18 as 
pp-GalNAc-T4L and pp-GalNAc-T20  as both pp-GalNAc-T17 and pp-GalNAc-T6L. 
 
Figure 2: Homology model of pp-GalNAc-T6. The N-terminal domain is depicted in 
mid grey, the catalytic domain is in light grey and the lectin domain in dark grey. The 
predicted structure is shown in a ribbon representation (left) and a space-filling 
representation (right). The model was constructed using Phyre 2, in the intensive mode 
[84] using sequence NP_009141, minimized using YASARA [85] and visualized using 
PyMol (www.pymol.org). The protein structure file is provided as electronic 
supplementary information. 
 
Scheme 1: The structure of UMP-hexadecanesulfonic-anhydride, an inhibitor of pp- 
GalNAc-T family enzymes. 
 
Scheme 2: Two uridine derivatives identified from a medium-throughput screen which 
inhibit members of the pp-GalNAc-T family of enzymes. The names are those used in 
the original paper reporting their synthesis and inhibitory potential [66]. 
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pp-GalNAc-T6 is over-expressed in cancer cells, but under-explored in terms of its 
biochemistry. Current evidence suggests that selective inhibition of this enzyme may result 
in an effective, novel anti-cancer and anti-metastasis treatment. 
